Drug Trial Radar · NCT06231381
Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP)
Last checked: Nov 19, 2026Latest source record: Mar 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
33
Planned (sponsor's estimate)
Start
Feb 29, 2024
Primary completion
Feb 13, 2025
Study completion Nov 30, 2025
Sponsor
- Lead sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 30, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase II, multicenter, double-blind, randomized, placebo parallel-controlled clinical trial to evaluate the efficacy and safety of HB0034 in patients with generalized pustular psoriasis (GPP) presenting with an acute flare of moderate to severe intensity.
Conditions
- Generalized Pustular Psoriasis (GPP)
Interventions
HB0034Drug
Anti-IL-36R antibody
PlaceboOther
non-biologically active drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects who achieved GPPGA pustulation subscore of 0/1 (no/almost no visiable pustules) at Week 1.Time frame: Week 1
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital (PKUPH)
Beijing, China · Recruiting
Shanghai Huaota Biopharmaceutical Co., Ltd
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.